> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Intradigm - URL: https://www.whiteroseintelligence.com/intradigm/ - Published: 1999-01-02T18:35:00.000Z - Updated: 2025-01-02T23:33:12.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization **Intradigm Corporation** was an American biotechnology company based in Rockville, Maryland. ## History Intradigm was founded in mid-2000 by [Jill Glasspool-Malone](https://www.whiteroseintelligence.com/Jill-Glasspool-Malone), Jim Mixson and Martin Woodle.[\[1\]](#fn1) The company's non-viral gene delivery technology was originally developed by Genetic Therapies, Inc. (GTI) and licensed to Intradigm by Novartis after their several attempts at gene therapy failed.[\[2\]](#fn2) The license agreement was transferred to Intradigm contingent on funding from Emerging Technology Partners and Novartis’ own venture fund. Glasspool-Malone began working on the startup in August 1999 as Managing Director, helping to secure $2.3 million in venture capital funding, setting up laboratory and office facilities, and developing the company's scientific and business development plan.[\[3\]](#fn3) Intradigm entered the State of Maryland's Challenge Investment Fund program on September 20, 2000. Intradigm closed its Series A round of funding in June 2001, receiving a $300,000 investment from the Maryland Venture Fund (MVF).[\[1:1\]](#fn1) The company “entered in to a multi-year, multi-product development program” with DirectGene in December 2001 to “jointly develop products aimed at prostate and pancreatic cancer.”[\[4\]](#fn4) On November 22, 2002, Intradigm announced it had hired former [Novavax](https://www.whiteroseintelligence.com/Novavax) CEO John Spears as its Chairman and CEO.[\[5\]](#fn5)[\[6\]](#fn6) On December 16, 2009, Intradigm was acquired by Silence Therapeutics.[\[7\]](#fn7) ## Organization Investors in Intradigm include:[\[1:2\]](#fn1)[\[8\]](#fn8) - [Alta Partners](https://www.whiteroseintelligence.com/Alta-Partners) - Astellas Venture Management - Eli Lilly - Emerging Technology Parters - Frazier Healthcare Partners - Maryland Venture Fund - MediBIC Group - MP Healthcare Venture Management - Novartis Venture Fund - Roche Venture Fund ### Personnel | Name | Position | Notes | | ------------------------------------------------------------------------------------ | --------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------- | | [Jill Glasspool-Malone](https://www.whiteroseintelligence.com/Jill-Glasspool-Malone) | Co-founder and Managing Director | Wife and business partner of [Robert Malone](https://www.whiteroseintelligence.com/Robert-Malone) | | Martin Woodle | Co-founder, CEO and President, Chief Scientific Advisor, Board Member | \- | | Jim Mixson | Co-founder | \- | | John Spears | CEO | Former CEO of [Novavax](https://www.whiteroseintelligence.com/Novavax) | | David Strickler | VP, Operations and Finance | \- | | Patrick Lu | Executive VP, Genomics | \- | | Puthupparampil Scaria | VP, Synthetic Vectors | \- | | Casimir Eitner | Chief Business Officer | \- | | Robert Riley | Director | \- | | Paul Tolstoshev | Advisory Board Member[\[9\]](#fn9) | Formerly Vice President of Research at Genetic Therapies, Inc. | | Anton Wellstein | Advisory Board Member | Georgetown University | | Richard Heller | Advisory Board Member | University of South Florida | | Richard Gilbert | Advisory Board Member | University of South Florida | | Gert Storm | Advisory Board Member | Utrecht University | | Bruce Trapnell | Advisory Board Member | University of Cincinnati, formerly VP for Virology of Genetic Therapies, Inc. | | Dexi Liu | Advisory Board Member | University of Pittsburgh | | Joel Cohen | Advisory Board Member | University of the Pacific | | Joel Jessee | Advisory Board Member | Vice President of Atto Bioscience | | Hamid Ghandehari | Advisory Board Member | University of Maryland at Baltimore | | Archibald James Mixson | Member | University of Maryland at Baltimore | ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=pharmaceutical%5Fcompanies:intradigm) - [Housatonic](https://sites.google.com/housatonicits.com/home0004/research/intradigm-corp) --- 1. Bodnar, T. (2002). *Venture Capital Funds Annual Report July 2002* (p. 27). Maryland Department of Business & Economic Development. [↩︎](#fnref1) [↩︎](#fnref1:1) [↩︎](#fnref1:2) 2. Kirchweger, G. (2003). Genetic Therapies Inc.: tight-lipped for now. *Molecular Therapy, 7*(3), 293\. [↩︎](#fnref2) 3. *Jill Glasspool Malone.* ResearchGate. Retrieved March 4, 2023, from [↩︎](#fnref3) 4. *Collaborations.* DirectGene. Retrieved August 26, 2002, from [↩︎](#fnref4) 5. Ex-chief of Novavax hired as Intradigm CEO. (2002, November 28). *The Baltimore Sun*, C2\. [↩︎](#fnref5) 6. *Intradigm appoints John A. Spears Chairman and CEO.* (2002, December 2). PharmaBiz. [↩︎](#fnref6) 7. *Intradigm Corporation - Crunchbase Company Profile & Funding.* Crunchbase. Retrieved March 5, 2023, from [↩︎](#fnref7) 8. *Intradigm Corporation - Funding, Financials, Valuation & Investors.* Crunchbase. Retrieved March 5, 2023, from [↩︎](#fnref8) 9. *About Us.* Interdigm Corporation. Retrieved May 10, 2002, from [↩︎](#fnref9)